Candid Therapeutics signs $925m T-cell engager deal with WuXi Biologics
Candid plans to conduct first-in-human studies in 2026 as it continues its T-cell engager deal drive.
Autoimmune Disorders
CHMP recommends oral peanut allergy immunotherapy treatment for toddlers
Advanz Pharma’s liver disease drug pulled from European market after court hearing
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets
Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions
GSK to acquire Chimagen’s CMG1A46 for autoimmune disease
“Strategic market positioning” needed for Ebglyss to rival Dupixent in atopic dermatitis
